ARS Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	0.03	1.32	5.51	0	0	0
Revenue Growth (YoY)	-97.72%	-76.10%	-	-	-	-
Gross Profit	0.03	1.32	5.51	0	0	0
Selling, General & Admin	47.28	18.46	4.69	8.34	2.56	3.52
Research & Development	20.27	18.38	20.27	24.58	21.51	14.8
Operating Expenses	67.55	36.83	24.96	32.92	24.07	18.32
Operating Income	-67.52	-35.52	-19.45	-32.92	-24.07	-18.32
Interest Expense / Income	0	0	0	0.03	-0.1	0
Other Expense / Income	-13.16	-0.83	0.79	-	-	-0.74
Pretax Income	-54.37	-34.68	-20.24	-32.95	-23.97	-17.58
Net Income	-54.37	-34.68	-20.24	-32.95	-23.97	-17.58
Shares Outstanding (Basic)	95	40	29	3	1	1
Shares Outstanding (Diluted)	95	40	29	3	1	1
Shares Change	138.30%	38.39%	893.01%	339.94%	9.45%	-
EPS (Basic)	-0.57	-0.87	-0.70	-11.33	-36.27	-29.11
EPS (Diluted)	-0.57	-0.87	-0.70	-11.33	-36.27	-29.11
Free Cash Flow	-59.44	-40.28	-17.62	-32.11	-18.99	-17.32
Free Cash Flow Per Share	-0.62	-1.01	-0.61	-11.04	-28.74	-28.69
Gross Margin	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-225066.67%	-2698.78%	-353.32%	-	-	-
Profit Margin	-181216.67%	-2635.41%	-367.65%	-	-	-
Free Cash Flow Margin	-198136.67%	-3060.56%	-319.94%	-	-	-
EBITDA	-54.29	-34.65	-20.03	-31.21	-22.52	-16.16
EBITDA Margin	-180973.33%	-2632.83%	-363.78%	-	-	-
Depreciation & Amortization	0.07	0.03	0.21	1.71	1.55	1.42
EBIT	-54.37	-34.68	-20.24	-32.92	-24.07	-17.58
EBIT Margin	-181216.67%	-2635.41%	-367.65%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).